Is Choksi Laborator overvalued or undervalued?

As of 29 August 2025, the valuation grade for Choksi Laborator has moved from attractive to very attractive, indicating a strong positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 95.17, an EV to EBITDA of 15.08, and a PEG Ratio of 3.37, which suggest that while the company has high earnings expectations, it is not priced excessively compared to its growth potential.
In comparison to peers, Choksi Laborator's PE Ratio is higher than Apollo Hospitals at 69.47 and Max Healthcare at 92.6, both of which are considered very expensive. The EV to EBITDA ratio of 15.08 is also more favorable than that of Max Healthcare's 57.38, reinforcing the undervaluation narrative. Additionally, Choksi Laborator has significantly outperformed the Sensex over various periods, with a year-to-date return of 173.01% compared to the Sensex's 2.14%, further supporting its attractive valuation.